Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations

Abstract Omaveloxolone is approved for the treatment of Friedreich ataxia (FA) in patients aged ≥ 16 years and is under clinical development for pediatric patients. In the MOXIe study, alanine and aspartate aminotransferase (ALT and AST) elevations were among the most common treatment-emergent adver...

Full description

Bibliographic Details

Published in:	Neurology and Therapy
Main Authors:	Susan Perlman, Mathieu Anheim, Sylvia Boesch, James H. Lewis, David R. Lynch
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-06-01
Subjects:	Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Drug-induced liver injury (DILI) Friedreich ataxia Liver function test Nuclear factor-erythroid 2-related factor 2 (Nrf2)
Online Access:	https://doi.org/10.1007/s40120-025-00752-8